9.83
3.69%
0.35
시간 외 거래:
10.00
0.17
+1.73%
전일 마감가:
$9.48
열려 있는:
$9.51
하루 거래량:
78,813
Relative Volume:
0.86
시가총액:
$30.36M
수익:
$7.97M
순이익/손실:
$-75.74M
주가수익비율:
-5.1466
EPS:
-1.91
순현금흐름:
$-85.33M
1주 성능:
+5.02%
1개월 성능:
+20.47%
6개월 성능:
-51.46%
1년 성능:
-48.28%
Aligos Therapeutics Inc Stock (ALGS) Company Profile
명칭
Aligos Therapeutics Inc
전화
(800) 466-6059
주소
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2023-01-06 | 업그레이드 | Jefferies | Hold → Buy |
2023-01-06 | 업그레이드 | Piper Sandler | Neutral → Overweight |
2022-03-23 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
2022-01-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2022-01-06 | 다운그레이드 | Jefferies | Buy → Hold |
2021-09-09 | 개시 | SVB Leerink | Outperform |
2021-05-17 | 재개 | Piper Sandler | Overweight |
2020-11-10 | 개시 | Cantor Fitzgerald | Overweight |
2020-11-10 | 개시 | JP Morgan | Overweight |
2020-11-10 | 개시 | Jefferies | Buy |
2020-11-10 | 개시 | Piper Sandler | Overweight |
모두보기
Aligos Therapeutics Inc 주식(ALGS)의 최신 뉴스
Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024 - StockTitan
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Drop in Short Interest - MarketBeat
Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 5.4% – Here’s What Happened - Defense World
Aligos Therapeutics (NASDAQ:ALGS) Trading Down 5.4%Here's What Happened - MarketBeat
HC Wainwright Reiterates Buy Rating for Aligos Therapeutics (NASDAQ:ALGS) - Defense World
Aligos Therapeutics (NASDAQ:ALGS) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat
Aligos Therapeutics' (ALGS) Buy Rating Reiterated at HC Wainwright - MarketBeat
Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184 - The Manila Times
Aligos Therapeutics: ALG-055009 reduces liver fatty deposits in patients with metabolic-dysfunction associated steatohepatitis (MASH) - 2 Minute Medicine
Aligos Therapeutics (NASDAQ:ALGS) Shares Gap UpWhat's Next? - MarketBeat
Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 202 - The Manila Times
Aligos Therapeutics (NASDAQ:ALGS) Trading Down 8.4%Should You Sell? - MarketBeat
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Aligos Therapeutics (NASDAQ:ALGS) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Significant Increase in Short Interest - MarketBeat
Aligos Therapeutics (NASDAQ:ALGS) Trading 4.9% HigherStill a Buy? - MarketBeat
ALGS stock touches 52-week low at $7.22 amid market challenges By Investing.com - Investing.com South Africa
Aligos Therapeutics (NASDAQ:ALGS) Hits New 1-Year LowWhat's Next? - MarketBeat
ALGS stock touches 52-week low at $7.22 amid market challenges - Investing.com Australia
When the Price of (ALGS) Talks, People Listen - Stock Traders Daily
Aligos TherapeuticsIt's All About Chronic Hepatitis B - RTTNews
Aligos Therapeutics (NASDAQ:ALGS) Shares Down 6.2% - Defense World
Aligos Therapeutics (NASDAQ:ALGS) Trading Down 6.2%Should You Sell? - MarketBeat
Aligos Therapeutics appoints new VP of Business Development By Investing.com - Investing.com Australia
Aligos Therapeutics appoints new VP of Business Development - Investing.com
Aligos Therapeutics Appoints David Perry as Vice President of Business Development - The Manila Times
Aligos Therapeutics to Present at Investor Conferences in October - The Manila Times
(ALGS) Investment Analysis and Advice - Stock Traders Daily
Aligos Therapeutics keeps stock target, overweight rating on promising data By Investing.com - Investing.com Australia
Aligos Therapeutics names new chief medical officer By Investing.com - Investing.com Australia
Aligos Therapeutics keeps stock target, overweight rating on promising data - Investing.com
ALGSAligos Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Aligos Therapeutics names new chief medical officer - Investing.com
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer - StockTitan
Aligos Therapeutics stock hits 52-week low at $8.5 - Investing.com
Aligos Therapeutics stock hits 52-week low at $8.5 By Investing.com - Investing.com Canada
Aligos Therapeutics (NASDAQ:ALGS) Sets New 52-Week Low at $8.28 - MarketBeat
Aligos Therapeutics (NASDAQ:ALGS) Reaches New 52-Week Low at $8.28 - Defense World
Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Down to $14.16 - Defense World
Aligos Therapeutics' (ALGS) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Up to $10.18 - MarketBeat
Aligos Therapeutics (NASDAQ:ALGS) Earns “Buy” Rating from HC Wainwright - Defense World
Market Recap Check: Aligos Therapeutics Inc (ALGS)’s Negative Finish at 10.18, Up/Down -28.11 - The Dwinnex
Aligos Phase II results for ALG-055009 in MASH fail to impress - The Pharma Letter
Aligos shares maintain Buy rating with price target after study - Investing.com
Aligos reports positive data from Phase IIa MASH treatment trial - Clinical Trials Arena
Aligos reports progress in MASH treatment study - Investing.com
Aligos Therapeutics Inc (ALGS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):